Search Results
May 12, 2026, 09:53 ET Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
2026:In the initial 80 mg QD Phase 1b cohort (n=19), all patients were evaluable for efficacy by 24 weeks. Of these, 9/19 (47%) were in major molecular response (MMR), with 6/16 (38%) achieving MMR.In the randomized 60 mg and 120 mg QD Phase 1b cohorts (n=41), 26 patients were
More news about: Enliven Therapeutics, Inc.
May 12, 2026, 09:05 ET Dunkin'® and Jel Sert Bring Dunkin' Refreshers to a Pocket-Sized Stick Format with Singles To Go!
returning fan-favorite Peach Passionfruit Lemonade, each sugar-free, single-serve stick mixes with 16.9 ounces of water and contains just 5 calories, 80 mg of caffeine from green tea, and B vitamins.The retail expansion follows a strong digital debut earlier this year, with early performance signaling
More news about: Jel Sert
May 12, 2026, 09:00 ET Pop & Bottle Enters Functional Hydration Category With New Line of Matcha Coconut Water
with 25mg of caffeine and 640mg of natural electrolytesPomegranate Berry Matcha Coconut Water – Sweet blackberry and tart pomegranate with 25mg of caffeine and 600mg of natural electrolytesCitrus Matcha Coconut Water – Bright citrus and a hint of fresh ginger with 25mg of
More news about: Pop & Bottle
May 12, 2026, 09:00 ET RYZE Launches Three New Target-Exclusive Lattes Nationwide
finish. Made with our SUPER6™ mushroom blend and instant coffee for ~50 mg of natural caffeine.Matcha Latte ($9.99): Silky and subtly sweet with soft vanilla notes, featuring a boost from our SUPER6™ mushroom blend and ~20 mg of natural caffeine from high-quality matcha.Chai Latte
More news about: RYZE
May 12, 2026, 09:00 ET IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients
trials. These trials evaluated the safety and efficacy of monthly 2 mg intravitreal administration of IZERVAY in patients with GA secondary to AMD. For the first 12 months in both trials, patients were randomized to receive either IZERVAY 2 mg or sham monthly. There were 286 participants enrolled in GATHER1
More news about: Astellas Pharma Inc.
May 12, 2026, 08:30 ET Wall Street's Cardiac Bet: Where Diagnostics Meet the Money
showing patients with severe hypertriglyceridemia achieved an 83% median reduction in triglycerides over two years, with 96% reaching levels below 500 mg/dL, the threshold associated with acute pancreatitis risk. No adjudicated acute pancreatitis events occurred in any patient receiving plozasiran during
More news about: USA News Group
May 12, 2026, 08:03 ET Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
dependence and were refractory to, intolerant of, or ineligible for erythropoiesis-stimulating agents (ESAs). Ofirnoflast was administered orally at 2 mg once daily on a 5-days-on/2-days-off schedule for up to 32 weeks. The primary endpoint was hematological improvement (HI) per IWG 2018 criteria. Highlights
More news about: Halia Therapeutics
May 12, 2026, 08:00 ET Independent TÜV-Nord Testing Demonstrates PureForge Brakes Generate Less than Half of Euro 7 Non Exhaust Emission Limit
the technology-driven manufacturer of ultra-durable brake systems, today announced that its Atomic-Forged® brakes have been independently tested at 3.3 mg/km of brake particulate emissions under the WLTP UN GTR-24 test, which will underpin the upcoming Euro 7 non-exhaust emissions standards. The new regulations
More news about: PureForge
May 12, 2026, 07:05 ET Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
final doses as indicated: 15 mg cohort = 15 mg x 13 weeks; 30 mg cohort = 30 mg x 13 weeks; 60 mg cohort = 30 mg x 2 weeks, 60 mg x 11 weeks; 90 mg cohort = 30 mg x 2 weeks, 60 mg x 2 weeks, 90 mg x 9 weeks; 120 mg cohort = 30 mg x 2 weeks, 60 mg x 2 weeks, 90 mg x 2 weeks, 120 mg x 7 weeks. 3) All enrolled
More news about: Viking Therapeutics, Inc.
May 12, 2026, 07:00 ET Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
required by law.1. [Silverberg JI, Eichenfield LF, Armstrong AW, Bagel J, Lockshin B, Boh E, Koo J, Farberg AS, Goldberg MS, Quick AP, Lebwohl MG,] The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective,
More news about: Castle Biosciences, Inc.
May 12, 2026, 05:16 ET Rare Cannabinoid Company Launches Spring Into Summer Sale Featuring THCV Gummies, Mood Gummies, and CBN Products
Mood GummiesThese best-selling THC + CBC Mood Gummies contain 5mg of hemp-derived Delta-9-THC, 5mg of CBC, and 25mg of CBD per gummy. Customers often describe the tasty fresh lime and mint blend as mood enhancing, relaxing, and ideal as a hangover-free
More news about: Rare Cannabinoid Company
May 11, 2026, 16:01 ET HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
expansion of addressable patients. The VYVGART Hytrulo opportunity is further extended with positive Phase 3 data in ocular myasthenia gravis, increasing the MG addressable market by an additional 7,000 patients in the U.S. alone. Additionally, DARZALEX Faspro gained its 12th and 13th approved indications and
More news about: Halozyme Therapeutics, Inc.
May 11, 2026, 10:21 ET Aviation Fuel Additives Market Reshapes Aerospace Industry as SAF Adoption Gains Momentum | 6.2% CAGR | Persistence Market Research
aviation applications, with DCI-6A gaining preference in pipeline systems because of its enhanced protection efficiency at lower treatment rates of 3–9 mg/l. Their long operational history and proven performance across harsh aviation environments, including high-altitude and defense missions, continue to
More news about: Persistence Market Research Pvt. Ltd.
May 11, 2026, 09:42 ET Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
patients achieved a ≥20-point improvement, the threshold for a large to very large improvement, compared to 21% in placebo. Among patients titrated to 60 mg twice daily, absolute pVO2 change was +2.1 mL/kg/min, representing a placebo-adjusted gain of +0.9 mL/kg/min. 55% of high-dose patients achieved
More news about: Braveheart Bio
May 11, 2026, 08:31 ET MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.About MetaViaMetaVia
More news about: MetaVia Inc.
May 11, 2026, 08:00 ET Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
www.fda.gov/medwatch.CAPLYTA is available in 42 mg, 21 mg, and 10.5 mg capsules.US-CAP-2500827Please see full
More news about: Johnson & Johnson
May 11, 2026, 07:00 ET Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape
was observed with long-term treatment, and the overall safety profile is similar to that of PD-(L)1 monoclonal antibodies. Dose escalation up to 25.0 mg/kg did not reach the maximum tolerated dose (MTD), and no dose-limiting toxicities (DLTs) were observed.Pan-cancer Efficacy: LBL-024
More news about: Nanjing Leads Biolabs Co., Ltd.
May 11, 2026, 04:30 ET Trial Results Support At-Home Treatment of Edema in Heart Failure with Subcutaneous Furosemide as an Effective and Safe Alternative to Inpatient Hospital Care
The pharmaceutical component of Lasix ONYU is a novel, high-concentration formulation of the diuretic furosemide, at 30 mg/mL. It comes in a pre-filled glass cartridge containing 80 mg of furosemide in 2.67 mL. The Lasix ONYU Infusor consists of two main parts: the Reusable Unit and the Disposable Unit.
More news about: SQ Innovation
May 11, 2026, 04:03 ET India struggles with a quit success rate under 5%: Experts back OTC access to NRT across all formats and dosages, including 2 mg and 4 mg
Making 2 mg and 4 mg NRTs widely available through OTC channels supports public health goals while maintaining regulatory oversight."Respire-2026 RecommendationsTo support national tobacco control objectives, experts recommended:Retain 2 mg and 4 mg NRTs as
More news about: The Asian Coalition for Health Empowerment (ACHE)
May 08, 2026, 14:58 ET Novo Nordisk lança nova condição especial (combo) para Wegovy® 2,4 mg: na compra de duas canetas, a terceira sai sem custo para o paciente
realizou a aprovação da nova dosagem de Wegovy® 7,2 mg no Brasil, que demonstrou perda de peso de 25% em 1 a cada 3 pacientes e perda de peso média de 21% segundo o estudo STEP UP.¹ A nova dosagem aprovada de 7,2 mg deve ser aplicada com três injeções de 2,4 mg no mesmo dia, uma vez por semana, conforme orientação
More news about: Novo Nordisk
May 08, 2026, 06:35 ET Knight Therapeutics anuncia a aprovação regulatória do TAVALISSE® no Brasil
inibidor da tirosina quinase do baço (SYK) administrado por via oral. Atualmente, está disponível nos Estados Unidos como TAVALISSE (comprimidos de 100 mg e 150 mg) e na Europa sob a marca TAVLESSE, para o tratamento de pacientes adultos com trombocitopenia imune crônica (PTI) que apresentaram resposta insuficiente
More news about: Knight Therapeutics Inc.
May 08, 2026, 06:35 ET Knight Therapeutics anuncia la aprobación regulatoria de TAVALISSE® en Brasil
tirosina quinasa del bazo (SYK) administrado por vía oral. Actualmente se encuentra disponible en Estados Unidos como TAVALISSE (tabletas de 100 mg y 150 mg) y en Europa bajo la marca TAVLESSE, para el tratamiento de pacientes adultos con trombocitopenia inmune (PTI) crónica que han presentado una respuesta
More news about: Knight Therapeutics Inc.
May 08, 2026, 05:21 ET AIKO sichert sich die französische 5,5%-Mehrwertsteuerberechtigung unter dem strengen PPE2 V2 Carbon Standard
CO₂-Äquivalent pro kWc, berechnet nach der PPE2 V2-Methode - die am schwierigsten zu erreichende AnforderungMaterielle Grenzen: Silber < 14 mg/W, Blei < 0,1 %, Cadmium < 0,01 %Vollständige Rückverfolgbarkeit: Produktionsstandort, Siliziumherkunft und Herstellungskette dokumentiert
More news about: AIKO
May 08, 2026, 02:30 ET Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
moderate in severity)LEQEMBI (lecanemab-irmb) is available:Intravenous infusion: 100 mg/mLSubcutaneous injection: 200 mg/mLPlease see full
More news about: Eisai Co., Ltd.
May 07, 2026, 18:48 ET AIKO obtient l'éligibilité à la TVA française à 5,5 % dans le cadre de la norme carbone PPE2 V2
CO₂ par kWc, calculé selon la méthodologie PPE2 V2 - l'exigence la plus difficile à atteindre.Limites des matériaux : argent < 14 mg/W, plomb < 0,1 %, cadmium < 0,01 %.Traçabilité complète : le site de production, l'origine du silicium et la chaîne de fabrication
More news about: AIKO